Definium Therapeutics CMO Daniel Karlin Sells Shares
Daniel Karlin sold 10,035 shares of Definium Therapeutics, valued at $451,876, on June 25, 2026.
Key Points
- Daniel Karlin, the Chief Medical Officer of Definium Therapeutics, sold 10,035 shares on June 25, 2026, for approximately $451,876.
- Shares of Definium Therapeutics traded near $44.95 with a market cap of about $5.97 billion and a beta of 2.378.
- Analysts maintain a strong buy consensus with a mean price target of $56 for Definium Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Daniel Karlin, the Chief Medical Officer at Definium Therapeutics, Inc. (NasdaqGS: DFTX), sold 10,035 shares on June 25, 2026. The shares were sold at an average price of $45.03, resulting in a total transaction value of approximately $451,876. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 25, 2026, several insiders at Definium Therapeutics were involved in planned sales. Chief Executive Officer Robert Barrow sold 29,208 shares, while Chief Legal Officer Mark Sullivan sold 13,008 shares. Chief Commercial Officer Matthew Wiley and Chief Financial Officer Brandi Roberts also participated, selling 2,867 and 3,013 shares, respectively. Additionally, Daniel Karlin had purchased 100,000 shares on June 22, 2026, outside of any planned sale.
Definium Therapeutics, Inc. Stock Up 9.7%
Shares of Definium Therapeutics traded near $44.95 on Saturday. The company has a market cap of approximately $5.97 billion and a beta of 2.378, indicating higher volatility compared to the market. Its 52-week range spans from $6.40 to $47.01. The stock's 50-day moving average is $24.52, and its 200-day moving average is $17.07. Definium has a strong liquidity position with a current ratio of 4.692 and a quick ratio of 4.604, though it carries some debt with a debt-to-equity ratio of 14.622.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 24, 2026, Jones Trading maintained its buy rating on Definium Therapeutics with a $74 price target. Baird and Needham also maintained buy ratings on June 23, 2026, with targets of $57 and $50, respectively. Leerink Partners and Oppenheimer both reiterated buy ratings with targets of $52 and $60 on June 22, 2026. The consensus among analysts is a strong buy, with an average target price of $56.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biotechnology company focused on developing treatments for brain health disorders. Headquartered in New York, NY, and led by CEO Robert Barrow, the company employs 105 people. Its lead products include DT120, in Phase 3 trials for anxiety and depression, and DT402, in Phase 2a trials for autism spectrum disorder. Originally known as Mind Medicine (MindMed) Inc., the company rebranded to Definium Therapeutics in January 2026.
Bottom Line
Daniel Karlin's recent sale of shares in Definium Therapeutics is part of a planned trading strategy. Investors often track insider transactions for potential insights, but it's important to note these sales are not uncommon and may not reflect a lack of confidence. The company's stock remains volatile with a high beta, and analysts continue to recommend it as a strong buy with a promising price target.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.